Induction strategies in triple negative breast cancer enhanced sensitivity to PD-1 blockade.
Use of an electrical current to measure extracellular fluid volume — bioimpedance spectroscopy (BIS) — may identify postoperative breast cancer patients at risk for lymphedema at an earlier stage, when intervention may more effectively prevent progression.
Mammography-based deep learning (DL) breast cancer risk models are more accurate than models that consider traditional risk factors and breast density.
EndoPredict (EPclin) is prognostic for distant recurrence (DR) in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy
Although most believe that the correlation between breast pain and breast cancer is weak, many referring clinicians will order imaging.
The FDA has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.The ‘KATHERINE’ trial evaluated the safety and efficacy of Kadcyla vs trastuzumab.
These guidelines remove ambiguity regarding screening mammography recommendations for women in their 40s.
Agency considering new patient warnings and checklists for the implants.
Women with early, low-risk, hormone-driven breast cancer are less likely to have a recurrence of their disease if they have radiotherapy after surgery.
Subcutaneous trastuzumab was determined noninferior to intravenous trastuzumab for patients with HER2-positive early breast cancer.
Large studies examining the efficacy of intraoperative lidocaine infusions on breast cancer surgery-associated pain were found to be feasible.
Small decline seen in costs in first 12 months of care with personalized treatment based on recurrence scores
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
The search for robust biomarkers in the tumor immune microenvironment that could be predictive of response to immune checkpoint blockade is ongoing.
In the palbociclib/CCND-amplification arm of the NCI MATCH trial, 42% of patients had received more than 4 prior lines of therapy.
On multivariate analyses, high baseline levels of IL-6 and CRP, but not IL-8, were associated with shorter OS in patients with breast cancer receiving atezolizumab.
Results from this study showed that a close spatial distribution between CD3-positive T cells and cancer cells was a biomarker for response to pembrolizumab.
Resistance genes were found to be cell-line–specific.
The survival benefit of anastrozole/fulvestrant combination therapy was more pronounced in the subgroup of patients who did not have prior exposure to tamoxifen.